GlassScriptPhysician profile
Stephen Neil Finberg
NPI 1285626374
$4,414.84
in general payments reported to CMS, 2019-2025
36 companies · $668 in 2025
The $668 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,281 · 2020: $477 · 2021: $488 · 2022: $532 · 2023: $411 · 2024: $557 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,567 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.54 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $911.07 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Philips North America LLC | $433.38 | 2019-2024 | (6299) Dreamwear |
| Astrazeneca Pharmaceuticals LP | $359.67 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Genentech USA, INC. | $340.78 | 2019-2025 | Xolair |
| Insmed, INC. | $236.31 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $162.13 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $155.94 | 2020-2025 | Cuvitru, Hyqvia |
| Mylan Specialty L.P. | $155.00 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.07 | 2019-2022 | |
| Optinose US, INC. | $123.06 | 2020 | |
| Inspire Medical Systems, INC. | $120.71 | 2021 | |
| United Therapeutics Corporation | $115.98 | 2021-2025 | Tyvaso |
| Novartis Pharmaceuticals Corporation | $112.48 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $101.68 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $100.18 | 2019-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $85.36 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Baxter Healthcare | $82.71 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Electromed, INC. | $74.86 | 2022-2025 | Smartvest |
| Sanofi-Aventis U.S. LLC | $69.99 | 2025 | |
| Advanced Respiratory, INC | $64.58 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $54.19 | 2022 | |
| Viatris Specialty LLC | $52.89 | 2025 | Yupelri |
| Verona Pharma, INC. | $47.69 | 2025 | Ohtuvayre |
| Csl Behring | $47.66 | 2021-2025 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $40.56 | 2021-2022 | |
| Shire North American Group INC | $30.09 | 2019 | |
| Vifor Pharma, INC. | $27.68 | 2024 | Zemaira |
| Gilead Sciences, INC. | $27.02 | 2019 | |
| Kaleo, INC. | $26.74 | 2022 | |
| Pulmonx Corporation | $26.12 | 2019 | |
| Itamar Medical INC | $21.56 | 2022 | |
| Pfizer INC. | $19.43 | 2021 | |
| Covis Pharma Gmbh | $18.13 | 2022 | |
| Harmony Biosciences LLC | $17.90 | 2022 | |
| Lilly USA, LLC | $15.69 | 2025 | Zepbound |
| Inogen, INC. | $10.55 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Finberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.